Relationship of cancer and dual antiplatelet duration to long-term risk of ischaemic and bleeding outcomes after percutaneous coronary intervention
Patients with cancer have higher risks of ischaemic and bleeding outcomes after PCI. However, we found no evidence that DAPT duration should differ from current guidelines in patients with cancer after PCI.
Authors
- Edwin Mandieka
- David Gagnon (ORCID: https://orcid.org/0000-0002-6367-3179)
- Scott Kinlay (ORCID: https://orcid.org/0000-0001-7687-9136)
- Ramael Ohiomoba (ORCID: https://orcid.org/0000-0003-2021-2804)
- Melissa Young
Institutions
- Boston University (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Veterans of Foreign Wars (US)
- Lemuel Shattuck Hospital (US)
- VA Boston Healthcare System (US)
Publication Details
- Journal
- European Heart Journal Open
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1093/ehjopen/oeaf163
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00